bath institute for rheumatic diseases
bath institute for rheumatic diseases Company Information
Company Number
02908933
Next Accounts
Dec 2025
Shareholders
-
Group Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
+1Registered Address
d1 wolfson building, royal united hospitals bath nhs, bath, BA1 3NG
Website
http://birdbath.org.ukbath institute for rheumatic diseases Estimated Valuation
Pomanda estimates the enterprise value of BATH INSTITUTE FOR RHEUMATIC DISEASES at £92k based on a Turnover of £106.9k and 0.86x industry multiple (adjusted for size and gross margin).
bath institute for rheumatic diseases Estimated Valuation
Pomanda estimates the enterprise value of BATH INSTITUTE FOR RHEUMATIC DISEASES at £744.6k based on an EBITDA of £151.4k and a 4.92x industry multiple (adjusted for size and gross margin).
bath institute for rheumatic diseases Estimated Valuation
Pomanda estimates the enterprise value of BATH INSTITUTE FOR RHEUMATIC DISEASES at £2.9m based on Net Assets of £1.8m and 1.62x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Bath Institute For Rheumatic Diseases Overview
Bath Institute For Rheumatic Diseases is a live company located in bath, BA1 3NG with a Companies House number of 02908933. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in March 1994, it's largest shareholder is unknown. Bath Institute For Rheumatic Diseases is a mature, micro sized company, Pomanda has estimated its turnover at £106.9k with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Bath Institute For Rheumatic Diseases Health Check
Pomanda's financial health check has awarded Bath Institute For Rheumatic Diseases a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
6 Weak
Size
annual sales of £106.9k, make it smaller than the average company (£3.5m)
£106.9k - Bath Institute For Rheumatic Diseases
£3.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 5%, show it is growing at a slower rate (6.8%)
5% - Bath Institute For Rheumatic Diseases
6.8% - Industry AVG
Production
with a gross margin of 42%, this company has a comparable cost of product (42%)
42% - Bath Institute For Rheumatic Diseases
42% - Industry AVG
Profitability
an operating margin of 141.2% make it more profitable than the average company (4.4%)
141.2% - Bath Institute For Rheumatic Diseases
4.4% - Industry AVG
Employees
with 1 employees, this is below the industry average (39)
- Bath Institute For Rheumatic Diseases
39 - Industry AVG
Pay Structure
on an average salary of £133.1k, the company has a higher pay structure (£50.2k)
- Bath Institute For Rheumatic Diseases
£50.2k - Industry AVG
Efficiency
resulting in sales per employee of £106.9k, this is less efficient (£129.3k)
- Bath Institute For Rheumatic Diseases
£129.3k - Industry AVG
Debtor Days
it gets paid by customers after 18 days, this is earlier than average (44 days)
18 days - Bath Institute For Rheumatic Diseases
44 days - Industry AVG
Creditor Days
its suppliers are paid after 250 days, this is slower than average (40 days)
250 days - Bath Institute For Rheumatic Diseases
40 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Bath Institute For Rheumatic Diseases
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 17 weeks, this is less cash available to meet short term requirements (43 weeks)
17 weeks - Bath Institute For Rheumatic Diseases
43 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 6.9%, this is a lower level of debt than the average (38.5%)
6.9% - Bath Institute For Rheumatic Diseases
38.5% - Industry AVG
BATH INSTITUTE FOR RHEUMATIC DISEASES financials
Bath Institute For Rheumatic Diseases's latest turnover from March 2024 is £106.9 thousand and the company has net assets of £1.8 million. According to their latest financial statements, we estimate that Bath Institute For Rheumatic Diseases has 1 employee and maintains cash reserves of £44.6 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 106,886 | 163,447 | 123,786 | 92,719 | 122,924 | 139,814 | 998,366 | 53,440 | 71,614 | 634,691 | 249,936 | 208,617 | 295,408 | 275,518 | 462,773 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 220,366 | 273,503 | 282,722 | 192,742 | |||||||||||
| Gross Profit | 29,570 | -64,886 | 12,686 | 82,776 | |||||||||||
| Admin Expenses | 4,667 | 6,592 | 4,924 | 1,955 | |||||||||||
| Operating Profit | 24,903 | -71,478 | 7,762 | 80,821 | |||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | 572 | ||||||||||||||
| Pre-Tax Profit | 115,039 | -142,906 | 75,212 | 172,928 | -239,501 | -99,485 | 780,302 | -193,979 | -79,698 | 402,197 | 64,468 | -28,246 | 22,179 | 84,377 | 137,425 |
| Tax | |||||||||||||||
| Profit After Tax | 115,039 | -142,906 | 75,212 | 172,928 | -239,501 | -99,485 | 780,302 | -193,979 | -79,698 | 402,197 | 64,468 | -28,246 | 22,179 | 84,377 | 137,425 |
| Dividends Paid | |||||||||||||||
| Retained Profit | 115,039 | -142,906 | 75,212 | 172,928 | -239,501 | -99,485 | 780,302 | -193,979 | -79,698 | 402,197 | 64,468 | -28,246 | 22,179 | 84,377 | 137,425 |
| Employee Costs | 133,060 | 119,611 | 99,490 | 111,081 | 113,458 | 108,952 | 48,100 | 46,515 | 58,746 | 121,223 | 110,147 | 139,215 | 146,391 | 145,526 | |
| Number Of Employees | |||||||||||||||
| EBITDA* | 31,794 | -64,431 | 16,077 | 93,444 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,786 | 667 | 943 | 1,219 | 288 | 757 | 1,653 | 2,599 | 3,543 | 2,225 | 262,480 | 268,335 | 275,382 | 283,697 | 297,008 |
| Intangible Assets | |||||||||||||||
| Investments & Other | 1,871,796 | 1,674,963 | 1,736,569 | 1,602,145 | 1,314,170 | 1,403,023 | 1,333,137 | 977,898 | 1,004,822 | 387,964 | 115,007 | 108,878 | 102,100 | 99,151 | |
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 1,873,582 | 1,675,630 | 1,737,512 | 1,603,364 | 1,314,458 | 1,403,780 | 1,334,790 | 980,497 | 1,008,365 | 390,189 | 377,487 | 377,213 | 377,482 | 382,848 | 297,008 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 5,513 | 8,767 | 6,812 | 6,851 | 4,846 | 22,733 | 8,418 | 15,497 | 10,557 | 23,973 | 50,358 | 80,992 | 33,970 | 29,554 | 59,107 |
| Group Debtors | 22,093 | 78,733 | 83,845 | 83,879 | 93,134 | ||||||||||
| Misc Debtors | 261 | 861 | 11,472 | 2,947 | 6,435 | 45,771 | 40,261 | 7,761 | 1,327 | 337 | 561 | 7,238 | 76,214 | 9,197 | 31,980 |
| Cash | 44,602 | 48,995 | 151,545 | 259,598 | 460,491 | 538,535 | 673,274 | 219,811 | 137,155 | 764,153 | 268,991 | 160,845 | 149,141 | 178,328 | 260,173 |
| misc current assets | |||||||||||||||
| total current assets | 50,376 | 58,623 | 169,829 | 269,396 | 471,772 | 607,039 | 721,953 | 243,069 | 149,039 | 810,556 | 398,643 | 332,920 | 343,204 | 310,213 | 351,260 |
| total assets | 1,923,958 | 1,734,253 | 1,907,341 | 1,872,760 | 1,786,230 | 2,010,819 | 2,056,743 | 1,223,566 | 1,157,404 | 1,200,745 | 776,130 | 710,133 | 720,686 | 693,061 | 648,268 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 42,542 | 14,325 | 29,191 | 29,859 | 13,021 | 12,771 | 16,088 | 9,469 | 7,912 | 7,456 | 14,240 | 26,751 | 11,984 | 12,519 | 12,868 |
| Group/Directors Accounts | 2,511 | 2,743 | |||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 89,778 | 43,329 | 58,645 | 140,503 | 243,739 | 229,077 | 242,085 | 154,889 | 69,588 | 34,103 | 21,743 | 13,832 | 17,684 | 14,650 | 49,832 |
| total current liabilities | 132,320 | 57,654 | 87,836 | 170,362 | 256,760 | 241,848 | 258,173 | 166,869 | 80,243 | 41,559 | 35,983 | 40,583 | 29,668 | 27,169 | 62,700 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 132,320 | 57,654 | 87,836 | 170,362 | 256,760 | 241,848 | 258,173 | 166,869 | 80,243 | 41,559 | 35,983 | 40,583 | 29,668 | 27,169 | 62,700 |
| net assets | 1,791,638 | 1,676,599 | 1,819,505 | 1,702,398 | 1,529,470 | 1,768,971 | 1,798,570 | 1,056,697 | 1,077,161 | 1,159,186 | 740,147 | 669,550 | 691,018 | 665,892 | 585,568 |
| total shareholders funds | 1,791,638 | 1,676,599 | 1,819,505 | 1,702,398 | 1,529,470 | 1,768,971 | 1,798,570 | 1,056,697 | 1,077,161 | 1,159,186 | 740,147 | 669,550 | 691,018 | 665,892 | 585,568 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 24,903 | -71,478 | 7,762 | 80,821 | |||||||||||
| Depreciation | 430 | 276 | 276 | 329 | 588 | 896 | 946 | 994 | 770 | 4,016 | 6,891 | 7,047 | 8,315 | 12,623 | 12,809 |
| Amortisation | |||||||||||||||
| Tax | |||||||||||||||
| Stock | |||||||||||||||
| Debtors | -3,854 | -8,656 | 8,486 | -1,483 | -57,223 | 19,825 | 25,421 | 11,374 | -34,519 | -83,249 | -42,423 | -21,988 | 62,178 | 40,798 | 91,087 |
| Creditors | 28,217 | -14,866 | -668 | 16,838 | 250 | -3,317 | 6,619 | 1,557 | 456 | -6,784 | -12,511 | 14,767 | -535 | -349 | 12,868 |
| Accruals and Deferred Income | 46,449 | -15,316 | -81,858 | -103,236 | 14,662 | -13,008 | 87,196 | 85,301 | 35,485 | 12,360 | 7,911 | -3,852 | 3,034 | -35,182 | 49,832 |
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | 69,617 | -31,528 | -43,602 | 17,115 | |||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | -393,668 | 20,661 | |||||||||||||
| Change in Investments | 196,833 | -61,606 | 134,424 | 287,975 | -88,853 | 69,886 | 355,239 | -26,924 | 616,858 | 272,957 | 6,129 | 6,778 | 2,949 | 99,151 | |
| cash flow from investments | -748,907 | 47,585 | |||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -2,511 | -232 | 2,743 | ||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | 572 | ||||||||||||||
| cash flow from financing | 41,895 | 69,886 | -40,940 | 173,283 | 416 | 16,842 | 6,701 | 6,778 | 2,947 | -4,053 | 448,143 | ||||
| cash and cash equivalents | |||||||||||||||
| cash | -4,393 | -102,550 | -108,053 | -200,893 | -78,044 | -134,739 | 453,463 | 82,656 | -626,998 | 495,162 | 108,146 | 11,704 | -29,187 | -81,845 | 260,173 |
| overdraft | |||||||||||||||
| change in cash | -4,393 | -102,550 | -108,053 | -200,893 | -78,044 | -134,739 | 453,463 | 82,656 | -626,998 | 495,162 | 108,146 | 11,704 | -29,187 | -81,845 | 260,173 |
bath institute for rheumatic diseases Credit Report and Business Information
Bath Institute For Rheumatic Diseases Competitor Analysis
Perform a competitor analysis for bath institute for rheumatic diseases by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in BA1 area or any other competitors across 12 key performance metrics.
bath institute for rheumatic diseases Ownership
BATH INSTITUTE FOR RHEUMATIC DISEASES group structure
Bath Institute For Rheumatic Diseases has 1 subsidiary company.
Ultimate parent company
BATH INSTITUTE FOR RHEUMATIC DISEASES
02908933
1 subsidiary
bath institute for rheumatic diseases directors
Bath Institute For Rheumatic Diseases currently has 9 directors. The longest serving directors include Mr James Sherwin (Aug 2008) and Dr Rajiv Sengupta (Nov 2012).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr James Sherwin | 91 years | Aug 2008 | - | Director | |
| Dr Rajiv Sengupta | England | 53 years | Nov 2012 | - | Director |
| Dr Amanda MacKenzie | 54 years | Nov 2012 | - | Director | |
| Mr Christopher Johns | 78 years | Sep 2014 | - | Director | |
| Dr Charles Tillett | England | 49 years | Mar 2016 | - | Director |
| Dr Neil McHugh | 70 years | Jun 2018 | - | Director | |
| Mr Shane O'Reilly | England | 61 years | Apr 2023 | - | Director |
| Mrs Linda Snelus | England | 64 years | Apr 2023 | - | Director |
| Professor Bernard Morley | England | 66 years | Apr 2023 | - | Director |
P&L
March 2024turnover
106.9k
-35%
operating profit
150.9k
0%
gross margin
42%
+0.19%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
1.8m
+0.07%
total assets
1.9m
+0.11%
cash
44.6k
-0.09%
net assets
Total assets minus all liabilities
Similar Companies
bath institute for rheumatic diseases company details
company number
02908933
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
72190 - Other research and experimental development on natural sciences and engineering
74990 - Non-trading company
incorporation date
March 1994
age
31
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
March 2024
previous names
N/A
accountant
TOM CASE
auditor
-
address
d1 wolfson building, royal united hospitals bath nhs, bath, BA1 3NG
Bank
UNITY TRUST BANK
Legal Advisor
STONE KING
bath institute for rheumatic diseases Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to bath institute for rheumatic diseases.
bath institute for rheumatic diseases Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BATH INSTITUTE FOR RHEUMATIC DISEASES. This can take several minutes, an email will notify you when this has completed.
bath institute for rheumatic diseases Companies House Filings - See Documents
| date | description | view/download |
|---|
